EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte Studie

Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism

Zhaobao Shi, Kunqing Xiao, Tianming Gao, Shengjie Jin, Chi Zhang, Baohuan Zhou, Dousheng Bai, Guoqing Jiang

Thrombosis and Haemostasis · 01.09.2025 · 125 (09) · 871-879

DOI: 10.1055/a-2484-0747 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2025. Verfasst von Zhaobao Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital, Yangzhou, China. Hauptthemen laut MEDLINE: Aspirin, Factor Xa Inhibitors, Hypersplenism, Liver Cirrhosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Clinical Research Project of Jiangsu Commission of Health, National Natural Science Foundation of China, The Top Talent Scientific Research Project of "Six One Projects".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Portal vein system thrombosis (PVST) is a frequent and possibly fatal concurrent disorder following splenectomy. The optimal anticoagulant to prevent PVST following splenectomy remains unclear. The purpose of this study was to compare the safety and efficacy of apixaban versus aspirin in preventing PVST after laparoscopic splenectomy (LS) for cirrhotic hypersplenism. In this single-center randomized controlled trial, 80 patients with liver cirrhosis who received LS were randomly allocated to two treatment arms that were treated with apixaban or aspirin for 6 months. The primary effectiveness outcome was PVST formation after LS. We excluded four patients who withdrew from the study. The dynamic incidence of PVST, main and intrahepatic branches of PVST, and splenic vein thrombosis in the 6 postoperative months were all significantly lower in the apixaban treatment arm compared to the aspirin treatment arm (all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinFactor Xa InhibitorsHypersplenismLiver CirrhosisPyrazolesPyridonesVenous ThrombosisAdultFemaleHumansMaleMiddle AgedIncidenceLaparoscopyPortal VeinRisk FactorsSplenectomyTreatment Outcome

Substanzen

apixabanAspirinFactor Xa InhibitorsPyrazolesPyridones

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital, Yangzhou, China.
  • The Yangzhou School of Clinical Medicine of Dalian Medical University, Dalian, Liaoning, China.
  • Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China.

Förderung

  • Clinical Research Project of Jiangsu Commission of Health
  • National Natural Science Foundation of China
  • The Top Talent Scientific Research Project of "Six One Projects"
  • Ministry of Science and Technology of the People's Republic of China
  • The Top Talent Scientific Research Project of “Six One Projects”

Zitieren

APA

Shi, Z., Xiao, K., Gao, T., Jin, S., Zhang, C., Zhou, B., Bai, D., & Jiang, G. (2025). Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism. Thrombosis and Haemostasis, 125(09), 871-879. https://doi.org/10.1055/a-2484-0747

Vancouver

Shi Z, Xiao K, Gao T, Jin S, Zhang C, Zhou B, et al. Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism. Thrombosis and Haemostasis. 2025;125(09):871-879. doi:10.1055/a-2484-0747

BibTeX
@article{Shi2025,
  author = {Shi, Zhaobao and Xiao, Kunqing and Gao, Tianming and Jin, Shengjie and Zhang, Chi and Zhou, Baohuan and Bai, Dousheng and Jiang, Guoqing},
  title = {Comparison of Apixaban and Aspirin in Preventing Portal Vein Thrombosis after Laparoscopic Splenectomy for Cirrhotic Hypersplenism},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {09},
  pages = {871--879},
  doi = {10.1055/a-2484-0747}
}
Kostenlos starten →